Impact of Gadolinium-enhancing (GD+) Lesions on No Evidence of Disease Activity (NEDA) Status in Subcutaneous Interferon Beta-1a (SC IFNβ-1a)-treated Patients

Abstract

Background: SC IFNβ-1a treatment after clinically isolated syndrome (CIS) increases chances of NEDA status vs delayed treatment (DT) after clinically-definite multiple sclerosis (CDMS). The impact of baseline gd+ lesions on NEDA using data from reflex/reflexion is assessed.